Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Dakota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Dakota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Dakota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Roberto Ferro Valdes (NPI 1861780108)

Field	Value
Entity Type	Individual
Organization	Roberto Ferro Valdes
Address	1000 E 23rd St Ste 200
City	Sioux Falls
State	SD
ZIP	57105
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 20, 2011

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

ROBERTO FERRO VALDES is listed as a Hematology & Oncology Physician in SIOUX FALLS, SD with an NPI enumerated 2011-07-20 (~15 years ago), indicating roughly a decade and a half of billing activity under this National Provider Identifier. This tenure supports a stable Medicare billing footprint concentrated in oncology drug and infusion services.

This provider's Medicare revenue totals $1.1M while there is no Medicaid billing on file, making the practice effectively single‑payer (Medicare) in the claims data shown. The absence of Medicaid activity suggests limited engagement with Medicaid-managed populations or that billing flows under another NPI/organization for non‑Medicare payers.

Revenue is highly concentrated in a small number of high-cost injectable oncology agents: the top three Medicare codes account for 71.6% of this provider's total Medicare revenue. Specifically, J9271 accounts for $431.2K (41.0%), J9144 accounts for $212K (20.1%), and J9312 accounts for $110.3K (10.5%) of the provider's Medicare revenue.

The code mix is consistent with an infusion-centered oncology practice focused on high-cost monoclonal antibody and immunotherapy treatments: J9271 (pembrolizumab), J9144 (daratumumab), and J9312 (rituximab) are the top revenue drivers, and chemotherapy administration/infusion codes such as 96413 and 96415 also appear on the top list. This pattern indicates the provider delivers office/clinic-based IV oncology therapies rather than primarily procedural or surgical oncology services.

Despite the high dollar concentration in J9271 (pembrolizumab), the provider's national competitive standing for that code is modest: J9271 ranks #1206 of 1841 providers nationally (34th percentile) and is described as typical, unremarkable volume for this code. In other words, while J9271 drives the largest share of this provider's Medicare revenue, the provider is not a high‑volume national outlier for that drug.

Daratumumab and rituximab volumes are similarly modest on a national scale: J9144 ranks #460 of 615 providers (24th percentile) and J9312 ranks #272 of 317 providers (13th percentile), both labeled typical, unremarkable volume for those codes. These percentiles indicate limited market share nationally for the other two top drugs despite their material contribution to this provider's internal revenue mix.

Evaluation-and-management and chemotherapy administration codes show routine outpatient follow-up and infusion practice activity: 99214 generated $30.7K (2.9% of Medicare revenue) and ranks #97777 of 479517 providers (80th percentile; typical, unremarkable volume), while chemotherapy administration code 96413 generated $31.1K (3.0% of Medicare revenue) and ranks #1853 of 7514 providers (75th percentile; typical, unremarkable volume). This combination of E/M and infusion claims is consistent with longitudinal oncology care delivered in an outpatient setting.

From a risk/quality signal perspective, none of the top-billed codes are labeled as outliers in the dataset provided; the plain‑English characterization for leading codes is uniformly "typical, unremarkable volume." There are, however, several low national percentiles for specific supporting codes (for example, J1568 ranks #366 of 381 providers, 4th percentile) that reflect relatively small national footprints on certain adjunct therapies despite the provider's local reliance on infused oncology drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	9,800	$40	$431.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,580	$40	$212K
J9312	Injection, rituximab, 10 mg	1,750	$60	$110.3K
J1437	Injection, ferric derisomaltose, 10 mg	2,700	$20	$43.2K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	930	$30	$31.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	300	$100	$31.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	310	$100	$30.7K
J0897	Injection, denosumab, 1 mg	1,140	$20	$21.7K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	60	$360	$21K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	230	$90	$19.8K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Dakota Distribution

Roberto Ferro Valdes — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Dakota

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	9,800	$40	$406.7K
J9144	1	10	5,580	$40	$213.9K
J9312	3	10	1,850	$60	$158.7K
J0897	33	40	2,460	$20	$52.8K
J1437	1	10	2,700	$20	$43.8K
J1568	1	10	930	$30	$31.9K
J1454	1	10	60	$360	$21K
Q5122	1	10	230	$90	$19.9K
96413	1	10	110	$100	$13.5K
96401	1	10	230	$60	$13.5K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Roberto Ferro Valdes, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Jamal Misleh	DE	Hematology & Oncology Physician	$6.8M	$0
Dhaval Shah	DE	Hematology & Oncology Physician	$2.5M	$0
Gregory Masters	DE	Medical Oncology Physician	$2.3M	$0
Evan Lapinsky	DE	Hematology & Oncology Physician	$1.7M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Amy Mcghee Jez	DE	Hematology & Oncology Physician	$1.1M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Roberto Ferro Valdes, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
South Dakota Achieve	SD	Developmental Disabilities Clinic/Center	$0	$166.9M
Dakotabilities	SD	Voluntary or Charitable Agency	$0	$77.8M
Sanford Medical Center	SD	Family Medicine Physician	$0	$68.8M
Volunteers Of America, Dakotas	SD	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$60.9M
Southeastern Behavioral Healthcare	SD	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$59.1M
Resouces For Human Development, Inc.	SD	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$31.1M
Sanford Medical Center	SD	General Acute Care Hospital	$0	$24.4M
Childrens Dental Center	SD	Pediatric Dentistry	$0	$24M
Sanford Medical Center	SD	Air Ambulance	$0	$11.9M
Avera Mckennan	SD	Family Medicine Physician	$0	$10.6M

Roberto Ferro Valdes — Billing Profile & Reimbursement Data

Sign up for Roberto Ferro Valdes — Billing Profile & Reimbursement Data policy alerts

Roberto Ferro Valdes — Billing Profile & Reimbursement Data

Sign up for Roberto Ferro Valdes — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References